Active infection not adequately responding to appropriate therapy
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.
Persons with an infection that is not responding to antimicrobial therapy
Has an active infection requiring systemic therapy; antimicrobial prophylaxis will be permitted at the discretion of the treating investigator
Active infection not adequately responding to appropriate therapy
Active infection not responding to appropriate therapy as determined by study chair
Active infection that is not responding to antimicrobial therapy
Have an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)
Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >=  degree Celsius)
Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
RECIPIENT: Active infection refractory to antimicrobial therapy
Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy; the protocol principal investigator (PI) is the final arbiter of eligibility
Active infection that is not responding to antimicrobial therapy
Uncontrolled infections not responding to antimicrobial therapy or requiring intensive critical care or vasopressors
Active infection, chronic or severe infection requiring ongoing antimicrobial therapy.
Active infection; any systemic antimicrobial therapy must be completed >=  days prior to initiation of protocol therapy
Uncontrolled infection not responding to appropriate antimicrobial treatment after  days; study chair is the final arbiter
Uncontrolled infections not responsive to antimicrobial therapy requiring intensive critical care
Active infection not adequately responding to appropriate therapy.
Active infection that is not responding to antimicrobial therapy
required parenteral antimicrobial therapy for active, intercurrent infections
Active infection not adequately responding to appropriate therapy.
Uncontrolled infection within  days before study enrollment\r\n* Infection treated with appropriate antimicrobial therapy and without signs of progression/treatment failure does not constitute an exclusion criterion
Uncontrolled infection within  days prior to enrollment \r\n* Infection treated with appropriate antimicrobial therapy and without signs of progression/treatment failure does not constitute an exclusion criterion
Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy; the principal investigator (PI) is the final arbiter of eligibility
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Uncontrolled infectious complications not responsive to appropriate antimicrobial therapy
Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >=  degree Celsius)
Active infections not responding to therapy; all efforts should be made to clear the infection prior to enrollment
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Active infection that is not responding to antimicrobial therapy
Uncontrolled infections not responsive to antimicrobial therapy requiring intensive critical care
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Active or chronic recurrent systemic infections that require continuous antimicrobial therapy during the Kevetrin study period
Oral treatment with antimicrobial therapy starting less than two weeks prior to first dose.
Active infection not controlled with appropriate antimicrobial therapy
Active systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within  weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable)
Active infection that is not responding to antimicrobial therapy
Patients using prophylactic antimicrobial locks in the CVC at the time of enrollment and those who are scheduled to receive antimicrobial locks in the CVC as part of a treatment plan are ineligible
Uncontrolled infections that are not responsive to antimicrobial therapy
Active infection not controlled with appropriate antimicrobial therapy
Active infection not controlled with appropriate antimicrobial therapy
Active infection requiring antimicrobial treatment that would interfere with interpretation of adverse events, cutaneous reactions or efficacy. Treatment of minor concurrent infections should be limited to less than  days.
